GlassScriptPhysician profile
Mohammed Zafar
NPI 1811951064
$21,160.16
in general payments reported to CMS, 2019-2025
25 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $18K · 2021: $1,057 · 2022: $201 · 2023: $77.92 · 2024: $98.22 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17,841.94 | 2020-2022 | |
| Medtronic USA, INC. | $1,115.34 | 2019 | |
| Supernus Pharmaceuticals, INC. | $775.18 | 2019-2021 | |
| Abbvie INC. | $231.82 | 2021-2025 | |
| Pfizer INC. | $172.80 | 2023-2025 | |
| Biogen, INC. | $155.39 | 2019-2023 | Vumerity |
| Amgen INC. | $147.30 | 2019-2022 | |
| Celgene Corporation | $92.35 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $79.64 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $55.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $52.73 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $49.51 | 2019 | |
| Avanir Pharmaceuticals, INC. | $37.16 | 2019 | |
| Acadia Pharmaceuticals INC | $34.05 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.67 | 2020 | |
| Amneal Pharmaceuticals LLC | $30.71 | 2020-2021 | |
| Kyowa Kirin, INC. | $30.60 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $28.45 | 2021 | |
| Tg Therapeutics, INC. | $26.67 | 2025 | |
| Janssen Biotech, INC. | $20.34 | 2025 | |
| Argenx US, INC. | $19.88 | 2024 | Vyvgart |
| Teva Pharmaceuticals USA, INC. | $19.71 | 2019 | |
| Ucb, INC. | $19.57 | 2025 | Rystiggo |
| Merz North America, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.